Wednesday, October 31, 2012
A report by the Government Accountability Office (GAO) on Part D prices, called "Discount Program Effects and Brand-Name Drug Price Trends," found that prescription costs did not go up for other people on Medicare as a result of discounts given by pharma firms to the government as a way of closing the gap in benefits for senior citizens.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.